Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
about
Targeting the phosphoinositide 3-kinase pathway in cancerDynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS).Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alphaPhosphatidylinositol 3-kinase: the oncoprotein.Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressorsDynamics of the phosphoinositide 3-kinase p110δ interaction with p85α and membranes reveals aspects of regulation distinct from p110αMultiscale mutation clustering algorithm identifies pan-cancer mutational clusters associated with pathway-level changes in gene expression.Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly.Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.Mice expressing activated PI3K rapidly develop advanced colon cancer.Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Class I PI3K in oncogenic cellular transformation.PI 3-kinase and cancer: changing accentsRGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3-kinase signaling.Assessing the subcellular distribution of oncogenic phosphoinositide 3-kinase using microinjection into live cells.An intramolecular interaction within the lipid kinase Fab1 regulates cellular phosphatidylinositol 3,5-bisphosphate lipid levels.Structural effects of oncogenic PI3Kα mutations.Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway.Potential role of PI3K inhibitors in the treatment of breast cancer.Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.Lobular breast cancer: pathology, biology, and options for clinical intervention.Administration of IκB-kinase inhibitor PS1145 enhances apoptosis in DMBA-induced tumor in male Wistar rats.Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.Scutellarein Reduces Inflammatory Responses by Inhibiting Src Kinase ActivityDomain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β.Prominent features of the amino acid mutation landscape in cancer.Insights into the pathological mechanisms of p85α mutations using a yeast-based phosphatidylinositol 3-kinase modelBlood-brain barrier-adapted precision medicine therapy for pediatric brain tumors.Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.Biophysical aspect of phosphatidylinositol 3-kinase and role of oncogenic mutants (E542K & E545K).p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal.Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin
P2860
Q29615809-66C534ED-25B6-46F7-8859-08D30DE57953Q30538272-D7C445A8-B1F2-41CC-AD47-B7C17FD56CB9Q33716552-6C65D3C5-D8EA-4A4E-A398-56F138D4F0BCQ34100548-FA85BB91-5449-44B4-810B-7290EA65B8FBQ34203861-E01C3E67-2F44-46A6-AB22-07C88A9643E9Q34966603-3D5999FE-00C6-42D4-882D-EC942D251520Q35069497-E3E8D441-1A26-493C-BFD8-28D5E4A0AB09Q35161212-06B66312-A435-41BE-92EE-353F19881FA1Q36272766-666B9994-9409-47D3-955E-ED36F58D3CC4Q36525854-3A70A024-79C2-4CE6-A59E-65ADBF75DB54Q36642695-224C0167-9A3C-4617-8B27-A06FECA4FC3CQ36821064-44833833-72E3-4BEC-B8B4-0CA1BCF8A202Q36862768-DAACE4D5-4544-4B6F-9249-59529272D2A4Q37270450-216C9EC1-B207-4BD1-B769-9841B01610AAQ37351928-C4572884-1710-4110-9C80-5E916758A871Q37372117-7D389380-DCF6-49F3-BED3-1285DFDD445FQ37700992-D8F83FF3-E6D5-4B92-BA42-307817F8B02FQ37744178-69ABB333-D3B1-40E2-8C61-2744362E8DD3Q37769164-ECFBB903-6A9A-4D44-97E7-99DE0A57CDA7Q37775890-24B942BF-AFFC-4F9F-9DE4-5B5496EBF85BQ37783617-F95C7B57-02E5-415E-B729-97C1B0240F31Q37783931-F1ABED16-A016-4A6D-8FD4-8DAF64FB8245Q37992693-4B4EBE49-DF39-4095-8BB4-22853AF00987Q38130105-DF43C8A5-56CB-41BE-A4E8-F18AE3C3BA15Q38856248-758B8909-18CC-42AD-A55A-4FBD5E6886D5Q39766760-639844BE-9BB4-4809-B08A-F6BC1963F7C0Q40583577-3B46E64A-5EF4-4B04-BBDF-F50E69EC2070Q41348786-D352A752-840D-488C-AFA1-8D8A335D2160Q41512259-D20C395E-7689-466B-9405-EE8BD3D20215Q42316429-33CF9470-7941-49D3-8702-4C27E3097B74Q47282920-07DB3AD6-8248-4EBD-8419-FBD0B522E64FQ47972738-BEE45D67-8752-4E89-B583-A19A41886B10Q52897244-6685AA7A-D83B-4624-8F9D-0386ED02123CQ54332608-372B997C-0CF6-48C3-89B3-F45A71CACFC1Q54499186-0E661362-E15A-4873-8A16-8C9636111BF8Q58802176-C8F2ED8C-A348-49B0-8CF0-86BDEE54EDBA
P2860
Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Insights into the oncogenic ef ...... ructure of p110alpha/p85alpha.
@en
Insights into the oncogenic ef ...... ructure of p110alpha/p85alpha.
@nl
type
label
Insights into the oncogenic ef ...... ructure of p110alpha/p85alpha.
@en
Insights into the oncogenic ef ...... ructure of p110alpha/p85alpha.
@nl
prefLabel
Insights into the oncogenic ef ...... ructure of p110alpha/p85alpha.
@en
Insights into the oncogenic ef ...... ructure of p110alpha/p85alpha.
@nl
P2093
P2860
P356
P1433
P1476
Insights into the oncogenic ef ...... ructure of p110alpha/p85alpha.
@en
P2093
Chuan-Hsiang Huang
Diana Mandelker
L Mario Amzel
Sandra B Gabelli
P2860
P304
P356
10.4161/CC.7.9.5817
P577
2008-02-27T00:00:00Z